C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for C4 Therapeutics (CCCC) over the last 5 years, with Q3 2025 value amounting to -$0.44.
- C4 Therapeutics' EPS (Weighted Average and Diluted) fell 2571.43% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.67, marking a year-over-year increase of 176.47%. This contributed to the annual value of -$1.52 for FY2024, which is 4314.19% up from last year.
- Per C4 Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.44 for Q3 2025, which was down 2571.43% from -$0.37 recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.26 during Q2 2024, and registered a low of -$0.76 during Q4 2022.
- For the 5-year period, C4 Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.52, with its median value being -$0.51 (2021).
- As far as peak fluctuations go, C4 Therapeutics' EPS (Weighted Average and Diluted) tumbled by 14516.13% in 2022, and later soared by 6438.36% in 2024.
- Over the past 5 years, C4 Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.31 in 2021, then crashed by 145.16% to -$0.76 in 2022, then grew by 10.53% to -$0.68 in 2023, then increased by 26.71% to -$0.5 in 2024, then rose by 11.71% to -$0.44 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.44 in Q3 2025, compared to -$0.37 in Q2 2025 and -$0.37 in Q1 2025.